The goal of this study was to document rates of parental consent in a pilot study of newborn screening for FMR1 gene expansions, examine demographic characteristics of mothers who consented or declined, describe the reasons for their decision, and discuss ethical and social aspects of the consent process
Objective As technology advances, newborn screening will be possible for conditions not screened tod...
This paper explores fragile X newborn screening (FXNBS) from the perspective of parents whose newbor...
Abstract Background Biomarkers of exposures such as infection or environmental chemicals can be meas...
The goal of this study was to document rates of parental consent in a pilot study of newborn screeni...
BACKGROUND: Delays in the diagnosis of children with fragile X syndrome (FXS) suggest the possibilit...
The possibility of newborn screening for fragile X syndrome is complicated by the potential for iden...
To determine caregiver perceptions about population screening for fragile X and examine factors pote...
Circumstances surrounding parental availability and decision-making were examined in the setting of ...
Genomic advances have contributed to a proliferation of newborn screening (NBS) programs. Psychosoci...
Purpose We surveyed parents to ascertain interest in newborn genomic testing and determine whether t...
Background: The current neonatal screening program ("the heel prick") involves taking a few drops of...
Recent advances in genomic sequencing and genomic medicine are reshaping the landscape of clinical c...
With the development of new genetic sequencing technologies, comes a timely opportunity to revisit t...
Introduction The goal of newborn bloodspot screening (NBS) is the early detection of treatable disor...
The analysis in this part of the report is grounded in the rights-based Code of Rights, and takes in...
Objective As technology advances, newborn screening will be possible for conditions not screened tod...
This paper explores fragile X newborn screening (FXNBS) from the perspective of parents whose newbor...
Abstract Background Biomarkers of exposures such as infection or environmental chemicals can be meas...
The goal of this study was to document rates of parental consent in a pilot study of newborn screeni...
BACKGROUND: Delays in the diagnosis of children with fragile X syndrome (FXS) suggest the possibilit...
The possibility of newborn screening for fragile X syndrome is complicated by the potential for iden...
To determine caregiver perceptions about population screening for fragile X and examine factors pote...
Circumstances surrounding parental availability and decision-making were examined in the setting of ...
Genomic advances have contributed to a proliferation of newborn screening (NBS) programs. Psychosoci...
Purpose We surveyed parents to ascertain interest in newborn genomic testing and determine whether t...
Background: The current neonatal screening program ("the heel prick") involves taking a few drops of...
Recent advances in genomic sequencing and genomic medicine are reshaping the landscape of clinical c...
With the development of new genetic sequencing technologies, comes a timely opportunity to revisit t...
Introduction The goal of newborn bloodspot screening (NBS) is the early detection of treatable disor...
The analysis in this part of the report is grounded in the rights-based Code of Rights, and takes in...
Objective As technology advances, newborn screening will be possible for conditions not screened tod...
This paper explores fragile X newborn screening (FXNBS) from the perspective of parents whose newbor...
Abstract Background Biomarkers of exposures such as infection or environmental chemicals can be meas...